• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Aptevo Therapeutics Reports First Quarter 2018 Financial Results

    Gabrielle Lakusta
    May. 10, 2018 08:52AM PST
    Biotech Investing

    Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and reported its financial results for the first quarter ended March 31, 2018. As quoted in the press release: “Turning to our ADAPTIR platform, enrollment is progressing in our otlertuzumab Phase 2 clinical study in peripheral …

    Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and reported its financial results for the first quarter ended March 31, 2018.

    As quoted in the press release:

    “Turning to our ADAPTIR platform, enrollment is progressing in our otlertuzumab Phase 2 clinical study in peripheral T-cell lymphoma and our APVO414 Phase 1 clinical study in metastatic castration resistant prostate cancer. We anticipate reporting preliminary top-line data from each of these programs at the end of the year. We also recently announced an IND filing for APVO436, and anticipate moving this program into the clinic in the fourth quarter of 2018.  New preclinical data for APVO436 were presented at this year’s AACR annual meeting and were very favorably received by the medical and financial communities. The data, comparing APVO436 to an Aptevo-generated version of a competitor molecule, showed reduced cytokine release, positioning APVO436 potentially as a best-in-class molecule in the CD123 field.  Finally, we are on track to file a second IND in the fourth quarter of 2018 for our autoimmune bispecific candidate, APVO210, and anticipate this molecule will enter the clinic next year.  We believe the unique mechanism of action of APVO210, which retains the immunosuppressive function of IL-10 without inducing immuno-stimulation demonstrated in preclinical studies, positions this molecule very competitively in the autoimmune therapeutic field,” said Mr. White.

    Click here to read the full press release.

    aptevo therapeuticsoncology and hematology therapeuticsfinancial resultsclinical study
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×